Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

STATUS

Recruiting
End date

Dec 5, 2026
participants needed

104
sponsor

Peking University

Send

Updated on 19 February 2024

See if I qualify

cancer

breast cancer

platelet count

neutrophil count

adenocarcinoma

bisphosphonate

targeted therapy

ejection fraction

invasive breast cancer

trastuzumab

cancer chemotherapy

inflammatory breast cancer

bisphosphonate therapy

pyrotinib

primary lesion

HER2

her2+ breast cancer

Summary

This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate (pCR) for adenocarcinoma.

Description

This study is a single-arm, open, phase II clinical study. The subjects are patients with locally advanced, inflammatory, or early HER2-positive breast cancer. The patients enter the trial period after signing informed consent. This study aims to evaluate trastuzumab The pathological complete response rate (pCR) of anti-combined pyrrotinib and chemotherapy (TCbH+Py) in the treatment of HER2-positive breast cancer.

The subjects began to take continuous medication after joining the group, and the total duration of medication was 6 cycles. Three to four weeks after the end of treatment, the surgeon will choose radical mastectomy, modified radical mastectomy or breast-sparing surgery according to the individual conditions of the patient. Regardless of whether the pCR is achieved, the adjuvant trastuzumab therapy or trastuzumab plus pertuzumab therapy is continued after the operation, and the total course of anti-HER2 therapy is up to 1 year (about 18 treatment cycles). According to the clinical stage and molecular classification of the tumor, it is necessary to decide whether adjuvant radiotherapy, chemotherapy and endocrine therapy are needed.

After the subject finishes all treatments, the subjects who are out of the group for non-PD and non-death causes need to receive the validity Follow-up until PD, start receiving other anti-tumor drug treatment or death (whichever comes first).

Details

Condition	HER2-positive Breast Cancer
Age	18-70 years
Treatment	Trastuzumab combined with Pyrotinib and chemotherapy
Clinical Study Identifier	NCT04481932
Sponsor	Peking University
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Female between 18 and 70 years old
	Histologically confirmed as invasive breast cancer
	ECOG PS 0-1
	The expected survival time is not less than 12 weeks
	Standard immunohistochemical HER2-positive breast cancer patients (IHC +++ or FISH amplification)
	The status of hormone receptors (ER and PR) can be known
	Clinical examination or imaging examination of primary lesion >2cm
	Patients who are operable (T2-3, N0-1, M0), locally advanced (T2-3,N2-3, M0 or T4A-C, any N, M0) or inflammatory breast cancer (T4d, any N, M0) and who have not received any previous anti-tumor therapy (including radiotherapy, chemotherapy, targeted therapy, except those who have received bisphosphonate therapy previously)
	Echocardiography indicated left ventricular ejection fraction (LVEF)55%
	Adequate organ and bone marrow function, as defined below: a. Neutrophil count (ANC) 1,500/mm3 (1.5 109/L); B. Platelet count (PLT) 100,000/mm3(100 109/L); C. Hemoglobin (Hb) 9 g/dL(90 g/L); D. Serum creatinine 1.5 times upper limit of normal value (ULN) or creatinine clearance 60 ml/min(based on Cockroft - Gault formula); E. Total bilirubin (BIL) 1.5 times the upper limit of normal value (ULN); F. AST/SGOT or ALT/SGPT 2.5 times upper limit of normal value (ULN);G. Urinary protein <2+; If urinary protein 2+, 24-hour urinary protein quantification shows protein must1 g or less
	I have agreed and signed the informed consent, and am willing and able to comply with the planned visit, research treatment, laboratory examination and other test procedures
Exclusion Criteria
	Have received any previous anti-tumor treatment for primary invasive breast cancer
	Previous (<10 years) or other malignant tumors, except for curable cancer species: a. basal cell carcinoma of skin and squamous cell carcinoma b. Carcinoma in situ of cervix
	For patients with other malignancies, they can also be included in the study if the time from diagnosis to enrollment exceeds 10 years; Prior surgical treatment is permitted except for radiotherapy or systemic therapy (chemotherapy or endocrine therapy)
	Metastatic breast cancer (M1), bilateral or ipsilateral multifocal breast cancer
	Uncontrolled hypertension, systolic blood pressure > 150 MMHG and/or diastolic blood pressure > 100 MMHG), or clinical symptomatic cardiovascular disease, myocardial ischemia and myocardial infarction, severe/unstable angina, poor control of cardiac arrhythmias (including women according to Bazett formula correction QTc interphase < 470 ms), symptoms of congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic cerebral embolism), NYHA magnitude cardiac insufficiency
	Receive other anti-tumor treatments within 4 weeks before enrollment
	Inability to swallow, intestinal obstruction or other factors affecting the use and absorption of medication
	Persons with allergic constitution or known history of allergy to the drug components of the program
	The patient has a severe concomitant disease or other conditions that the researcher considers inappropriate for the patient to participate in the studyIn any case
	Non-surgically sterilized female patients of childbearing age must have negative serum or urine HCG tests within 14 days prior to study inclusion; And must be non-lactation
	Other circumstances deemed inappropriate for inclusion by the researcher

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

invasive breast cancer

trastuzumab

cancer chemotherapy

inflammatory breast cancer

bisphosphonate therapy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer